Carnitine taken by itself or in conjunction with the cancer treatment
drug Doxorubicin presents a new potential approach for the treatment of ovarian and other cancers.
It is the story of a potential medical advancement and a call for patient volunteers for a clinical study to test its effectiveness in patients with ovarian cancer.
Stephen L. DeFelice, M.D. has spent a good portion of his career studying the medical benefits of Carnitine. Scientific studies report that when taken in conjunction with the commonly prescribed cancer fighting chemotherapy drug, Doxorubicin, it reduces Doxorubicin's toxic effects on the heart as well provides its own cancer cell fighting properties.
This website tells the story of this potential scientific breakthrough how it was discovered, developed, and is implemented in today's new fight against cancer.
Also, Dr. DeFelice, founder of FIM, the Foundation for Innovation in Medicine and SDF Consultants, is now involved in a clinical study to evaluate the effectiveness of Carnitine used in conjunction with Doxorubicin in the treatment of ovarian cancer. A limited number of patient volunteers are now being sought to participate in this program at a northern New Jersey hospital.
Go directly to page with information on study participation.
Next page: What are Carnitine and Doxorubicin?